![]() | |
Clinical data | |
---|---|
Other names | BRN 0620708 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H14ClN3 |
Molar mass | 283.76 g·mol−1 |
3D model (JSmol) | |
| |
|
AW-15'1129 is a drug with an imidazo-quinazoline based structure. The pharmacology is described as antidepressant based on strong adrenergic and anti-REM effects. It was invented by Othmar Dr Schindler of Wander AG in the 1960's. Although the drug is not known to have ever been commercialized, it is a representative example of a psychochemical based on a rational synthetic design.
In the patent the dosage of API is formulated to a strength of 4mg per tablet.
Precursor is made from 2-aminobenzonitrile [1885-29-6] via cyclic aminal formation with the ethylenediamine. [6]
Ex 1: o-(1,4,5,6-tetrahydropyrimidin-2-yl)aniline [68100-63-0] hydrochloride salt [NA] (1) and benzaldehyde (2) are refluxed together in alcoholic acid to give 6-phenyl-2,3,6,7-tetrahydro-4H-pyrimido[1,2-c]quinazoline hydrochloride (3). Reduction with potassium borohydride gives 5-phenyl-2,3,5,6-tetrahydro-imidazo[1,2-c]quinazoline (4).
This article needs additional or more specific categories .(June 2025) |